Bureaucracy, aversion to risk, high taxes are blamed for why Japan lags behind in the start-up scene. Read more at straitstimes.com.

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Daiichi Sankyo Company with a $41.55 average price target. The company has a one-year high of $44.64 and a one ...

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...

Our collaboration with Daiichi Sankyo is an exciting opportunity to unlock therapeutic access to new cell types, paving the way for precision treatments that can transform patient outcomes.” ...

Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more ... Almost six years on, we're one of the fastest growing oncology companies in the world.

Daiichi Sankyo has signed a deal worth up to $300 million ... Delivering Enhertu subcutaneously could be one way to fend off rivals, including biosimilar versions of IV Enhertu, which could ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...